⚠️ FOR RESEARCH PURPOSES ONLY — All compounds and data are for in vitro laboratory research and educational reference only. Not for human or animal use. Not evaluated by the FDA.
Research Library 28 Compounds

Research Peptide Blog Database

Peer-reviewed studies, clinical data, mechanism breakdowns, and molecular specifications — all in one place.

🔍
Research Library GHRH Analog

GHRH(1-29) Analog · Growth Hormone Releasing Factor

Sermorelin

GHRH analog. For in vitro research use only.

FormulaC149H246N44O42S
Mol. Weight3357.93 g/mol
CAS86168-78-7
PubMed Indexed Research Use Only

Published Scientific Research

Peer-reviewed studies investigating Sermorelin sourced from PubMed-indexed journals for educational reference only.

In Vitro Study PubMed

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Drug testing and analysis 2021
Memdouh S, Gavrilović I, Ng K et al.

The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Although there is evidence of their use, based on admissions and intelligence, they do not...

View Full Study on PubMed →
In Vivo Study PubMed

Growth hormone releasing hormone.

Clinics in endocrinology and metabolism 1986
Grossman A, Savage MO, Besser GM et al.

Human growth hormone releasing hormone (GHRH) was originally extracted from two pancreatic tumours in patients with acromegaly, and is now known to consist of a 44 residue amidated peptide or its C-terminal-shortened derivatives. The sequence...

View Full Study on PubMed →
In Vitro Study PubMed

Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.

International journal of molecular sciences 2025
Gesmundo I, Pedrolli F, Giglioli FR et al.

Growth hormone-releasing hormone (GHRH) antagonists exert antitumor functions in different experimental cancers. However, their role in combination with radiotherapy in non-small cell lung cancer (NSCLC) remains unknown. Therefore, we investigated the radiosensitizing effect of GHRH...

View Full Study on PubMed →
In Vitro Study PubMed

Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).

The Prostate 2022
Muñoz-Moreno L, Carmena MJ, Prieto JC et al.

Growth hormone-releasing hormone (GHRH) and its receptors have been implicated in the progression of various tumors. In this study, we analyzed the carcinogenetic potential of exposure to GHRH of a nontumor human prostate epithelial cell...

View Full Study on PubMed →
In Vivo Study PubMed

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.

Proceedings of the National Academy of Sciences of the United States of America 2011
Rick FG, Schally AV, Block NL et al.

Growth hormone-releasing hormone (GHRH), a hypothalamic polypeptide, acts as a potent autocrine/paracrine growth factor in many cancers. Benign prostatic hyperplasia (BPH) is a pathologic proliferation of prostatic glandular and stromal tissues; a variety of growth...

View Full Study on PubMed →
In Vivo Study PubMed

Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.

Proceedings of the National Academy of Sciences of the United States of America 2018
Schally AV, Wang H, He J et al.

The effects of the growth hormone-releasing hormone (GHRH) agonist MR409 on various human cancer cells were investigated. In H446 small cell lung cancer (SCLC) and HCC827 and H460 (non-SCLC) cells, MR409 promoted cell viability, reduced...

View Full Study on PubMed →
In Vivo Study PubMed

A glimpse at growth hormone-releasing hormone cosmos.

Clinical and experimental pharmacology & physiology 2020
Barabutis N et al.

Growth hormone-releasing hormone is a hypothalamic neuropeptide, which regulates the secretion of growth hormone by the anterior pituitary gland. Recent evidence suggest that it exerts growth factor activities in a diverse variety of in vivo...

View Full Study on PubMed →
Clinical Trial PubMed

Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).

Proceedings of the National Academy of Sciences of the United States of America 2012
Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG et al.

Both cardiac myocytes and cardiac stem cells (CSCs) express the receptor of growth hormone releasing hormone (GHRH), activation of which improves injury responses after myocardial infarction (MI). Here we show that a GHRH-agonist (GHRH-A; JI-38)...

View Full Study on PubMed →
Research Notice: All studies are presented for educational and informational purposes only. These compounds are for in vitro laboratory research use only (RUO). Not for human or animal use. Not evaluated or approved by the FDA.
Compound Information

Technical Specifications

🔬 Molecular Profile

TypeGHRH Analog
ClassificationSynthetic Analog
CAS Number86168-78-7
Mol. Weight3357.93 g/mol
FormulaC149H246N44O42S
OriginSynthetic

🧊 Storage Requirements

❄️
Lyophilized (powder) -20°C up to 2 years
💉
Reconstituted 2-8°C up to 30 days
⏱️
Working solution Use within 24 hours
Protect from light • Avoid repeated freeze-thaw cycles
Research Grade

Research-Grade Sermorelin

≥98% purity, third-party COA verified, lyophilized for stability. For in vitro laboratory research use only.

⚠️ Research Use Only. Not for human or animal use. Not evaluated or approved by the FDA.

⚠️ Important Research Notice

All compounds listed are intended exclusively for in vitro laboratory research by qualified professionals. Not for human or animal consumption. Not approved by the FDA for any diagnostic, therapeutic, or clinical purpose. All research findings are sourced from peer-reviewed journals for educational reference only. Not to be interpreted as medical advice or product claims.